Vir Biotechnology's (VIR) shares were up nearly 15% in recent Wednesday trading after BofA Securities upgraded the biopharmaceutical company's stock to buy from neutral, with a price target of $14.
Trading volume stood at over 5.7 million shares against a daily average of roughly 1.2 million.
Price: 5.10, Change: +0.66, Percent Change: +14.86